Abstract
BACKGROUND AND OBJECTIVE: Obesity is a global health issue closely linked to multiple cardiovascular and metabolic conditions. The renaming of nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated fatty liver disease (MAFLD) has sparked discussions about renaming nonalcoholic fatty pancreas disease (NAFPD). This narrative review explores the potential benefits and challenges of renaming NAFPD to metabolic dysfunction-associated fatty pancreas disease (MAFPD) and its potential clinical implications. METHODS: The review employs a narrative approach, synthesizing existing literature and expert opinions to evaluate the rationale behind and the possible implications of renaming NAFPD to MAFPD. KEY CONTENT AND FINDINGS: NAFPD is increasingly recognized worldwide but lacks standardized diagnostic criteria, hindering its independent classification as a disease. Renaming NAFPD to MAFPD may enhance diagnostic accuracy, prognostic prediction, and personalized treatment strategies. It may also facilitate global epidemiological research, data sharing, and collaboration. Major challenges include establishing uniform diagnostic guidelines for promoting and educating about the newly proposed terminology. CONCLUSIONS: The proposed renaming from NAFPD to MAFPD may offer promising benefits despite challenges. It may also lead to improved management and understanding of the disease, potentially benefiting global healthcare strategies aimed at addressing obesity-related pancreatic complications. KEYWORDS: Metabolic dysfunction-associated fatty liver disease (MAFLD); nonalcoholic fatty liver disease (NAFLD); metabolic dysfunction-associated fatty pancreas disease (MAFPD); nonalcoholic fatty pancreas disease (NAFPD); metabolic syndrome (MetS).